Critical Reviews in Oncology Hematology Critical Reviews in Oncology Hematology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment
Despite advances in therapy, metastatic castration-resistant prostate cancer (mCRPC) remains a deadly disease with poor long-term survival. Traditionally, docetaxel-based chemotherapy has been considered as a mainstay of treatment in patients progressing on androgen deprivation therapy (ADT). Management of mCRPC has significantly evolved with the introduction of cabazitaxel, abiraterone acetate, enzalutamide, and 223-radium dichloride, which are all associated with improved overall survival (OS) (Crawford et al., 2015) but, unfortunately, only limited data are available on the optimal sequence of newer agents in mCRPC (Att...
Source: Critical Reviews in Oncology Hematology - March 6, 2018 Category: Cancer & Oncology Authors: Marzia Del Re, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Elena Arrigoni, Elisa Biasco, Andrea Sbrana, Erika Coppi, Luca Galli, Sergio Bracarda, Daniele Santini, Romano Danesi Source Type: research

Treatment of spinal metastases in renal cell carcinoma: A critical review
Kidney cancer is the 9th most common cancer in men and the 14th most common in women worldwide. Renal cell carcinoma (RCC) constitutes 90% of all malignancies of the kidney. RCC, is known to be highly vascular and relatively radioresistant. Bone metastases are one of the most common metastatic sites and occur in around 30% of RCCs. They significantly impact the quality of life of patients causing pain and pathological fractures. Spinal metastases represent a particular case with regard to symptoms and treatment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 6, 2018 Category: Cancer & Oncology Authors: Diego Teyssonneau, Marine Gross-Goupil, Charlotte Domblides, Thibaud Haaser, Vincent Pointillart, Amaury Daste, Olivier Hauger, Alain Ravaud Source Type: research

Current perspectives on the crosstalk between lung cancer stem cells and cancer-associated fibroblasts
Lung cancer, in particular non-small cell lung carcinoma (NSCLC), is the second most common cancer in both men and women and the leading cause of cancer-related deaths worldwide. Its prognosis and diagnosis are determined by several driver mutations and diverse risk factors (e.g. smoking). While immunotherapy has proven effective in some patients, treatment of NSCLC using conventional chemotherapy is largely ineffective. The latter is believed to be due to the existence of a subpopulation of stem-like, highly tumorigenic and chemoresistant cells within the tumor population known as cancer stem cells (CSC). (Source: Critica...
Source: Critical Reviews in Oncology Hematology - March 6, 2018 Category: Cancer & Oncology Authors: Cristina Alguacil-N úñez, Inés Ferrer-Ortiz, Elena García-Verdú, Pilar López- Pirez, Irene Maria Llorente-Cortijo, Bruno Sainz Source Type: research

Metformin for non-small cell lung cancer patients: Opportunities and pitfalls
Despite exciting advances of the anticancer armamentarium in the recent years, mortality of non-small cell lung cancer (NSCLC) remains high and novel treatments are requisite. Therapy intensification is explored with promising, but expensive and potentially toxic new compounds. Repositioning already existing drugs for cancer treatment could save money and improve patient outcomes in specific contexts. Observational data suggest that use of the standard antidiabetic agent metformin decreases lung cancer incidence and mortality. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 6, 2018 Category: Cancer & Oncology Authors: Antonin Levy, J érôme Doyen Source Type: research

Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 6, 2018 Category: Cancer & Oncology Authors: Marzia Del Re, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Elena Arrigoni, Elisa Biasco, Andrea Sbrana, Erika Coppi, Luca Galli, Sergio Bracarda, Daniele Santini, Romano Danesi Source Type: research

Treatment of Spinal Metastases in Renal Cell Carcinoma: A Critical Review
Kidney cancer is the 9th most common cancer in men and the 14th most common in women worldwide. Renal cell carcinoma (RCC) constitutes 90% of all malignancies of the kidney. RCC, is known to be highly vascular and relatively radioresistant. Bone metastases are one of the most common metastatic sites and occur in around 30% of RCCs. They significantly impact the quality of life of patients causing pain and pathological fractures. Spinal metastases represent a particular case with regard to symptoms and treatment. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 6, 2018 Category: Cancer & Oncology Authors: Diego Teyssonneau, Marine Gross-Goupil, Charlotte Domblides, Thibaud Haaser, Vincent Pointillart, Amaury Daste, Olivier Hauger, Alain Ravaud Source Type: research

Current Perspectives on the Crosstalk Between Lung Cancer Stem Cells and Cancer-Associated Fibroblasts
Lung cancer, in particular non-small cell lung carcinoma (NSCLC), is the second most common cancer in both men and women and the leading cause of cancer-related deaths worldwide. Its prognosis and diagnosis are determined by several driver mutations and diverse risk factors (e.g. smoking). While immunotherapy has proven effective in some patients, treatment of NSCLC using conventional chemotherapy is largely ineffective. The latter is believed to be due to the existence of a subpopulation of stem-like, highly tumorigenic and chemoresistant cells within the tumor population known as cancer stem cells (CSC). (Source: Critica...
Source: Critical Reviews in Oncology Hematology - March 6, 2018 Category: Cancer & Oncology Authors: Cristina Alguacil N úñez, Inés Ferrer Ortiz, Elena García Verdú, Pilar López Pirez, Irene Maria Llorente Cortijo, Bruno Sainz Source Type: research

Metformin for non-small cell lung cancer patients: opportunities and pitfalls
Despite exciting advances of the anticancer armamentarium in the recent years, mortality of non-small cell lung cancer (NSCLC) remains high and novel treatments are requisite. Therapy intensification is explored with promising, but expensive and potentially toxic new compounds. Repositioning already existing drugs for cancer treatment could save money and improve patient outcomes in specific contexts. Observational data suggest that use of the standard antidiabetic agent metformin decreases lung cancer incidence and mortality. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 6, 2018 Category: Cancer & Oncology Authors: Antonin Levy, J érôme Doyen Source Type: research

Classic biphasic pulmonary blastoma: A case report and review of the literature
We describe an unusual case of classic biphasic pulmonary blastoma (CBPC), with long-term survival despite numerous and varied cancer-related events and review the literature. Our 71-year-old Caucasian woman presented with history of blood in sputum in 2009. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 3, 2018 Category: Cancer & Oncology Authors: H. Le Caer, E. Teissier, J.R. Barriere, N. Venissac Source Type: research

Classic biphasic pulmonary blastoma: a case report and review of the literature
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - March 3, 2018 Category: Cancer & Oncology Authors: Herv é Le Caer Source Type: research

Oral cancer in Fanconi anemia: Review of 121 cases
Fanconi anemia (FA) is a rare autosomal recessive genetic disorder characterized by aplastic anemia, progressive pancytopenia, congenital anomalies, and increased risk of cancer development. After hematopoietic stem cell transplant (HSCT), patients have an estimated 500-fold increase in the risk of developing head and neck cancer compared to a non-affected, and the oral cavity is affected in one-third of cases. Thus, this study aimed to better understand the natural history of oral cavity cancer in patients affected by FA. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 28, 2018 Category: Cancer & Oncology Authors: Camila Pinheiro Furquim, Allana Pivovar, Jos é Miguel Amenábar, Carmem Bonfim, Cassius Carvalho Torres-Pereira Source Type: research

Oral Cancer in Fanconi Anemia: Review of 121 cases
Fanconi anemia (FA) is a rare autosomal recessive genetic disorder characterized by aplastic anemia, progressive pancytopenia, congenital anomalies, and increased risk of cancer development. After hematopoietic stem cell transplant (HSCT), patients have an estimated 500-fold increase in the risk of developing head and neck cancer compared to a normal population, and the oral cavity is affected in one-third of cases. Thus, this study aimed to better understand the natural history of oral cavity cancer in patients affected by FA. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 28, 2018 Category: Cancer & Oncology Authors: Camila Pinheiro Furquim, Allana Pivovar, Jos é Miguel Céspedes Amenábar, Carmem Bonfim, Cassius Carvalho Torres-Pereira Source Type: research

Corrigendum to “Evaluation and management of skeletal disease in cancer care” [Crit. Rev. Oncol./Hematol. 120 (December 2017) 217–226]
The authors regret that the affiliations and acknowledgment were incorrect at the time of the article acceptance. This has now been corrected. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 26, 2018 Category: Cancer & Oncology Authors: Anuhya Kommalapati, Sri Harsha Tella, Mary Angelynne Esquivel, Ricardo Correa Tags: Corrigendum Source Type: research

Effect of anticoagulants on admission rates and length of hospital stay for acute venous thromboembolism: A systematic review of randomized control trials
There is a paucity of data available on hospitalization and length of stay (LOS) for different anticoagulant therapies. We sought to compare and summarize admission rates and LOS, and describe the frequency of reporting these two outcomes in randomized control trials (RCTs) comparing different anticoagulant therapies for venous thromboembolism (VTE). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 25, 2018 Category: Cancer & Oncology Authors: Yongzhe Hong, Sola Mansour, Ghazi Alotaibi, Cynthia Wu, Michael Sean McMurtry Source Type: research

Effect of anticoagulants on admission rates and length of hospital stay for acute venous thromboembolism: a systematic review of randomized control trials
There is a paucity of data available on hospitalization and length of stay (LOS) for different anticoagulant therapies. We sought to compare and summarize admission rates and LOS, and describe the frequency of reporting these two outcomes in randomized control trials (RCTs) comparing different anticoagulant therapies for venous thromboembolism (VTE). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 25, 2018 Category: Cancer & Oncology Authors: Yongzhe Hong, Sola Mansour, Ghazi Alotaibi, Cynthia Wu, Michael Sean McMurtry Source Type: research